Formycon AG (XTER:FYB) FCF Margin % : -29.93% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Formycon AG's Free Cash Flow for the six months ended in Dec. 2023 was €-10.15 Mil. Formycon AG's Revenue for the six months ended in Dec. 2023 was €33.91 Mil. Therefore, Formycon AG's FCF Margin % for the quarter that ended in Dec. 2023 was -29.93%.

As of today, Formycon AG's current FCF Yield % is -4.40%.

The historical rank and industry rank for Formycon AG's FCF Margin % or its related term are showing as below:

XTER:FYB' s FCF Margin % Range Over the Past 10 Years
Min: -107.39 Med: -16.46 Max: 28.46
Current: -39.96

During the past 13 years, the highest FCF Margin % of Formycon AG was 28.46%. The lowest was -107.39%. And the median was -16.46%.

XTER:FYB's FCF Margin % is ranked better than
63.89% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs XTER:FYB: -39.96

Formycon AG FCF Margin % Historical Data

The historical data trend for Formycon AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG FCF Margin % Chart

Formycon AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-7.52

-16.78

-39.04

-107.39

-39.96

Formycon AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-38.09	-70.55	-133.55	-47.72	-29.93

Competitive Comparison of Formycon AG's FCF Margin %

For the Biotechnology subindustry, Formycon AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Formycon AG's FCF Margin % falls into.

Formycon AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Formycon AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-31.044	/	77.696
	=	-39.96 %

Formycon AG's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-10.147	/	33.907
	=	-29.93 %

Formycon AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Formycon AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG (XTER:FYB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FYB:Germany FYB:Germany FYB:Germany

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.

Executives

Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines